Mizuho Upgrades FocalTherics (NASDAQ:FOCL) to “Strong-Buy”

FocalTherics (NASDAQ:FOCL) was upgraded by equities research analysts at Mizuho to a “strong-buy” rating in a note issued to investors on Friday,Zacks.com reports.

FOCL has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research note on Tuesday, June 2nd. Wall Street Zen lowered shares of FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

FocalTherics Trading Down 0.2%

NASDAQ:FOCL opened at $5.43 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79. The stock has a market cap of $203.52 million, a P/E ratio of -6.70 and a beta of -0.04. FocalTherics has a 52-week low of $1.21 and a 52-week high of $5.64.

FocalTherics (NASDAQ:FOCL) last announced its earnings results on Thursday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $20.48 million during the quarter, compared to analyst estimates of $19.46 million. FocalTherics had a negative net margin of 41.47% and a negative return on equity of 137.61%. As a group, analysts forecast that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Joshua Levine bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $4.22 per share, for a total transaction of $42,200.00. Following the completion of the acquisition, the director owned 35,000 shares of the company’s stock, valued at approximately $147,700. The trade was a 40.00% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Flax Pond Capital LLC acquired a new position in shares of FocalTherics during the 4th quarter worth approximately $2,623,000. Leonteq Securities AG acquired a new stake in shares of FocalTherics in the 4th quarter valued at approximately $313,000. Financial Planning Navigators CORP acquired a new stake in shares of FocalTherics in the 4th quarter valued at approximately $33,000. Kovack Advisors Inc. bought a new position in shares of FocalTherics in the fourth quarter valued at $53,000. Finally, Rock Springs Capital Management LP grew its stake in shares of FocalTherics by 1.3% in the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after buying an additional 16,500 shares in the last quarter. 62.74% of the stock is currently owned by institutional investors.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.